Related Experiment Video
Updated: Mar 30, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.5K
Top 10 Facts to Know About Inpatient Glycemic Control
William B Horton1, Jose S Subauste2
1Department of Medicine, University of Mississippi Medical Center, Jackson.
The American Journal of Medicine
|November 3, 2015
Summary
Uncontrolled hyperglycemia in hospitalized patients leads to poor outcomes and increased hospital stays. Effective inpatient glycemic control, including insulin therapy and discharge planning, is crucial for patient care.
Area of Science:
- Internal Medicine
- Endocrinology
- Hospital Management
Background:
- Uncontrolled hyperglycemia is prevalent in hospitalized patients, affecting those with and without prior diabetes diagnoses.
- Hyperglycemia is linked to adverse clinical outcomes and extended hospital stays.
- Diabetes-related hospitalizations represent a significant financial burden, accounting for half of all healthcare expenditures for the disease.
Purpose of the Study:
- To emphasize the importance of optimizing glycemic control in the inpatient setting.
- To outline essential components of effective inpatient hyperglycemia management.
Main Methods:
- Literature review and synthesis of current best practices in inpatient glycemic management.
- Focus on key strategies for managing hyperglycemia in hospitalized patients.
Main Results:
- Optimizing blood glucose levels is a critical priority for healthcare providers in hospitals.
- Effective management requires a multi-faceted approach tailored to individual patient needs.
Conclusions:
- Comprehensive inpatient glycemic control strategies are essential for improving patient outcomes.
- Key strategies include setting appropriate glycemic targets, preventing hypoglycemia, utilizing basal-bolus insulin, and ensuring seamless transition to outpatient care.
More Related Videos
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
1.4K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
01:15Hypoglycemia and Glucagon
1.3K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
01:06Oral Hypoglycemic Agents: Glinides
938
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
938
01:22Diabetes Mellitus: Type 2 and Gestational
5.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.5K
01:16Insulin: Dosing Regimen and Adverse Effects
1.2K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.2K
01:23Dipeptidyl Peptidase 4 Inhibitors
1.0K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.0K